+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Basaglar 2017 U.S. Promotional Audit Report

  • ID: 4615757
  • Report
  • Region: United States
  • 21 pages
  • MD Details
1 of 2
The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Basaglar through reportable promotional activity in 2017 and how does this compare to its peer set in the Type 1 Diabetes - Insulin and Type 2 Diabetes - Insulin markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Eli Lilly's depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, and Endocrinology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Basaglar throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Basaglar in 2017?
Data Sources and Methodology:
  • The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals.
  • Over 124,200 paid interactions across 33,400 physicians made on behalf of Basaglar were carefully examined to support our analysis.
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4615757
Adroll
adroll